Status:
COMPLETED
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
Lead Sponsor:
CMH Multan Institute of Medical Sciences
Conditions:
Iron Deficiency Anemia (IDA)
Pregnancy
Eligibility:
FEMALE
20-45 years
Phase:
PHASE4
Brief Summary
This clinical trial aimed to determine whether intravenous ferric carboxymaltose is more useful than iron sucrose for treating anemia in pregnant women. The main question it aimed to answer was: Is ...
Detailed Description
The study was conducted after the ethics review committee approval. A total of 60 pregnant women presenting to the department of Obstetrics and Gynecology and fulfilling the eligibility criteria were ...
Eligibility Criteria
Inclusion
- 28-34 weeks of gestation
- Iron deficiency anemia (IDA): IDA will be labelled if Hemoglobin is \<10 gm% and serum Ferritin \< 30 ng/ml.
Exclusion
- Hepatitis (serum transaminases more than 1.5 times the upper limit of normal) and HIV infection
- serum creatinine level of more than 2.0 mg/dL
- history of allergic reaction to intravenous iron infusion
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06911034
Start Date
February 1 2024
End Date
September 30 2024
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cmh Multan Institute of Medical Sciences
Multan, Punjab Province, Pakistan, 60000